# Evaluating True PCR-negative Rate of Frontline Dasatinib in Early Chronic Phase CML for Therapeutic Harmonization

> **NCT02975115** · — · UNKNOWN · sponsor: **Seoul St. Mary's Hospital** · enrollment: 102 (actual)

## Conditions studied

- Chronic Myelocytic Leukemia

## Interventions

- **OTHER:** RQ-PCR RNA Analysis

## Key facts

- **NCT ID:** NCT02975115
- **Lead sponsor:** Seoul St. Mary's Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-11
- **Primary completion:** 2016-11
- **Final completion:** 2018-01
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2016-11-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02975115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02975115, "Evaluating True PCR-negative Rate of Frontline Dasatinib in Early Chronic Phase CML for Therapeutic Harmonization". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02975115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*